Insulet (PODD) Revenue Growth (3y) (2013 - 2026)
Insulet (PODD) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 8.07% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 9.66% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 4.70% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 14.78% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 10.83% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 14.51% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 3.20% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 25.44% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 8.05% |
| 10 | Insulet | 10.31 Bn | 9.77 Bn | 562.60 Mn | 26.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.45% |
| Mar 31, 2026 | 28.61% |
| Dec 31, 2025 | 28.47% |
| Sep 30, 2025 | 27.50% |
| Jun 30, 2025 | 29.43% |
| Mar 31, 2025 | 24.42% |
| Dec 31, 2024 | 24.76% |
| Sep 30, 2024 | 27.60% |
| Jun 30, 2024 | 23.41% |
| Mar 31, 2024 | 20.52% |
| Dec 31, 2023 | 27.48% |
| Sep 30, 2023 | 22.74% |
| Jun 30, 2023 | 20.56% |
| Mar 31, 2023 | 21.84% |
| Dec 31, 2022 | 20.86% |
| Sep 30, 2022 | 21.06% |
| Jun 30, 2022 | 19.13% |
| Mar 31, 2022 | 22.78% |
| Dec 31, 2021 | 23.11% |
| Sep 30, 2021 | 20.11% |